

June 1, 2017

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza , Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: STAR

Dear Sirs,

Sub: Press Release


Please find attached press release issued by the Company titled:

**“Strides Shasun receives USFDA Approval for
Ibuprofen Tablets”**

Thanks & Regards,
For STRIDES SHASUN LIMITED



Manjula Ramamurthy
Company Secretary



Press Release

Thursday, June 1, 2017

Strides Shasun Limited
(Formerly Strides Arcolab Limited)
Strides House, Bannerghatta Road,
Bangalore – 560076.

Strides Shasun receives USFDA Approval For Ibuprofen Tablets

Product to be marketed under OTC brand Nuprin

Bangalore, June 1, 2017 Strides Shasun Limited today announced that it has received approval from the United States Food & Drug Administration (USFDA) for **Ibuprofen Tablets USP, 200 mg (OTC)**.

According to IRI data, the US market for Ibuprofen Tablets USP 200 mg (OTC) is approximately USD 520 Million. The approval further strengthens company's fast growing global OTC franchise. The product will be marketed by Strides Pharma Inc in the US Market under its OTC brand Nuprin.

About Ibuprofen Tablets

Ibuprofen is used to relieve pain from various conditions such as headache, dental pain, muscle aches, or arthritis. It is also used to reduce fever and to relieve minor aches and pain due to the common cold or flu. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID).

About Strides Shasun Limited

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients.



The Company has global manufacturing foot print with 8 manufacturing facilities spread across three continents including 6 US FDA approved facilities and 2 facilities for the emerging markets. The Company has three dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries. Additional information is available at the Company's website at www.stridesarco.com

For further information, please contact:

<u>Strides Shasun</u> Badree Komandur, Executive Director +91 80 6784 0747 Vikesh Kumar +91 80 6784 0827 Kannan. N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791	<u>PR Consultancy</u> Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com K Priya: +91 9535425418 priya@fortunapr.com
--	--

